Related Experiment Videos
Glycoprotein D adjuvant herpes simplex virus vaccine
1Cincinnati Children's Hospital Medical Center, Division of Infectious Diseases, University of Cincinnati, Cincinnati, OH 45229, USA. david.bernstein@cchmc.org
Expert Review of Vaccines
|October 14, 2005
Summary
A new genital herpes simplex virus (HSV) vaccine shows promise, reducing disease by over 70% in women without prior HSV infection. Further trials are ongoing to confirm its effectiveness against HSV-2.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Herpes simplex virus (HSV) types 1 and 2 cause significant infections, including genital herpes.
- Despite extensive research, effective HSV vaccines have been elusive until recent advancements.
Purpose of the Study:
- To review the efficacy and safety of a genital HSV-2 glycoprotein D subunit vaccine (gD2t) with the AS04 adjuvant.
- To provide context on other herpes vaccine development strategies.
Main Methods:
- Review of clinical trial data for the gD2t-AS04 vaccine.
- Evaluation of vaccine safety and efficacy in preventing genital herpes disease.
Main Results:
- The gD2t-AS04 vaccine demonstrated safety in multiple large clinical trials.
- The vaccine reduced genital herpes disease by 73-74% in females without prior HSV infection.
Conclusions:
- The gD2t-AS04 vaccine shows significant potential for preventing genital herpes in specific populations.
- Ongoing trials will further assess protection against HSV-2 infection and disease in seronegative females.